New understanding of the genomic diversity of ovarian cancer is already having an effect on drug development in the space, with a possible revival of AstraZeneca LP’s PARP inhibitor olaparib. The company confirms it is looking to tease out the effect of olaparib in a subset of ovarian cancer patients based on BRCA mutations, despite a previous announcement to terminate development in this indication.
Ovarian cancer is a relatively uncommon disease, with 22,000 new cases every year in the U.S., and some experts now...